AUTL

Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics (AUTL - Research Report) today and set a price target of $12.00. The company's shares opened today at $2.81.According to TipRanks, Blum is an analyst with an average return of -24.0% and a 27.47% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $12.25 average price target, a 335.94% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-remains-a-buy-on-autolus-therapeutics-autl?utm_source=advfn.com&utm_medium=referral